Epidermal Barrier Architecture: Cornified Envelope and Lipid Lamellae
Epidermal barrier (stratum corneum (SC); cornified envelope (CE) + extracellular lipid lamellae; two-compartment model: protein-rich corneocytes + lipid matrix (ceramide/cholesterol/fatty acid; 1:1:1 molar ratio)); keratinocyte terminal differentiation (spinous → granular → cornified): (1) granular layer proteins: FLG (filaggrin; profilaggrin 400 kDa → caspase-14/CASP14 + calpain → filaggrin monomers; FLG aggregates keratin filaments; NMF (natural moisturising factor): FLG → histidase/HYAL → free AA/urocanic acid/PCA → SC hydration; FLG mutation (ichthyosis vulgaris; atopic dermatitis predisposition; R501X/2282del4 common)); loricrin (LOR; Gly/Ser/Cys-rich; 80% CE protein by mass; cross-linked by TGM1/TGM3 isopeptide bonds Gln-Lys; LOR Nrf2/ARE target); involucrin (IVL; early CE marker; TGM1 substrate; also Nrf2/ARE target); envoplakin (EVPL; IVL scaffold); periplakin (PPL); TGM1/3 (transglutaminases; Ca2+-dependent; cross-link LOR/IVL/SPR into CE; TGM1 deficiency → lamellar ichthyosis); (2) lipid lamellae: lamellar bodies (LBs; membrane-bound organelles in SG; contain GluCer/GlcCer, SPC (sphingomyelin), PC, FFA; LB exocytosis at SG-SC interface → β-GCase (GBA1) GluCer → Cer; ABCA12 (lipid transporter; harlequin ichthyosis); ABCA3; sPLA2 (secreted phospholipase A2)); (3) serine protease regulation: KLK5/7 (kallikrein 5/7; SC serine proteases; profilaggrin/desmoglein/corneodesmosin cleavage; regulated by LEKTI (lymphoepithelial Kazal-type-related inhibitor; SPINK5 gene; pH-sensitive inhibition of KLK5/7; Netherton syndrome: SPINK5 loss → KLK5 hyperactive → SC barrier destruction + TSLP ↑)); caspase-14 (CASP14; keratinocyte-specific; FLG processing; Nrf2-regulated; profilaggrin → filaggrin monomers; CASP14 deficiency → elevated TEWL + UV sensitivity); TEWL (transepidermal water loss; quantifies barrier integrity; Tewameter; >15 g/m2/h abnormal).
Spirulina Mechanisms in Skin Barrier Biology
Nrf2→Terminal Differentiation Protein Expression
Nrf2 in keratinocyte differentiation (keratinocyte Nrf2 expression highest in SG/SC; Nrf2/ARE targets in skin: NQO1, HO-1, GCLC/GCLM, TXNRD1, CASP14, LOR/IVL (ARE-driven; Nrf2 binds ARE in LOR and IVL promoters; Nrf2 knockout mice: LOR ↓, IVL ↓, impaired CE cross-linking), ABCA12 (Nrf2/ARE in ABCA12 promoter; lipid transporter; Nrf2 → ABCA12 → GluCer loading into LBs → normal lipid lamellae); p21/CDKN1A (Nrf2 → p21 → cell cycle arrest → terminal differentiation induction)); caspase-14 (CASP14; ARE in CASP14 promoter; Nrf2 → CASP14 expression → filaggrin monomer generation → NMF → SC hydration): spirulina phycocyanobilin→Keap1 Cys151 alkylation → Nrf2 activation: LOR +20–30% (Western/RT-qPCR; primary keratinocyte differentiation model); IVL +15–25%; CASP14 +15–20%; NMF (urocanic acid/PCA by-products) +10–20% (indirect; NMF measured by HPLC of SC tape strips); TEWL −10–20% (murine tape-strip barrier disruption model; spirulina 4% topical vs systemic 5g/day oral models).
NF-κB Suppression of Th2 Cytokine FLG/Loricrin Downregulation
Th2 cytokines FLG suppression (atopic dermatitis (AD) immunopathology: Th2 skewed → IL-4/IL-13 ↓ FLG/LOR/IVL in keratinocytes; IL-4 receptor (IL4Rα/γc IL-4; IL4Rα/IL13Rα1 IL-13; → JAK1/JAK3 → STAT6 Tyr641 → STAT6 homodimer nuclear); STAT6 negative GAS sites in FLG/LOR/IVL promoters → Sp1/Ets displacement → transcriptional repression; TSLP (thymic stromal lymphopoietin; NF-κB/AP-1-driven in keratinocytes; protease/allergen-induced; TSLP → TSLPR/IL7Rα → JAK1/JAK2 → STAT5 → pDC/Th2 priming → IL-4/IL-13 → STAT6 → FLG ↓ vicious cycle); IL-33 (IL1 family; epithelial damage DAMP; NF-κB → IL-33 precursor; caspase-1/caspase-3 → active IL-33 secretion; ST2/IL1RL1 receptor → MyD88 → NF-κB/MAP kinase → Th2 amplification)): spirulina NF-κB inhibition: TSLP −30–50% (keratinocyte NF-κB↓; TSLP mRNA ↓; relevant to AD); IL-33 −25–40%; spirulina additionally: AMPK→JAK1 ↓ (AMPK phosphorylates JAK1 Ser515 → JAK1 activity ↓ → STAT6 Tyr641 ↓) → partially counters IL-4/IL-13 STAT6 → FLG suppression; net: FLG mRNA recovery in IL-4/IL-13-challenged keratinocytes +20–35% vs spirulina untreated; barrier functional recovery (TEER of organotypic skin model) +25–40%.
Ceramide Synthesis and Lamellar Body Lipid Support
Ceramide (Cer; major SC lipid barrier constituent; 50% SC lipid by weight; synthesised via: de novo (serine palmitoyltransferase SPT → 3-ketodihydrosphingosine → DHS → sphinganine → CerS1–6 (dihydroceramide synthase) → dihydroceramide → DEGS1 (desaturase) → Cer); or salvage (sphingomyelin → SMPD → Cer; GluCer → GBA1 → Cer)); PPARγ (peroxisome proliferator-activated receptor gamma; SC lipid gene regulation: PPARγ/RXRα → CerS3 (chain-length-specific; very long chain C24–C26 Cer dominant in SC); PPARγ ligands: 15-HETE/13-HODE (Nrf2→LOX modulation); PPARγ→ABCA12 → LB loading); AMPK-Cer axis: AMPK → SMPD (neutral sphingomyelinase; Ser261 phospho activation → Cer from SM → SK → S1P; OR AMPK→CerS expression via AMPK-CREB→CerS3 promoter): spirulina: (1) AMPK activation → CerS3/CerS5 expression +10–20% → long-chain Cer synthesis ↑; (2) Nrf2→NQO1→PPARγ ligand (NQO1 reduces PPARγ ligand quinone form; Nrf2→15-LOX→15-HETE modest increase → PPARγ activation → CerS3/ABCA12; (3) essential fatty acid (spirulina γ-linolenic acid/GLA ~1.1g/10g → eicosanoid substrate for 15-HETE → PPARγ); SC ceramide +10–20% (tape-strip lipidomics; murine; spirulina 8 weeks); TEWL −15–25% (combined LOR/IVL + Cer effects).
KLK5/SPINK5 Balance and Protease Regulation
KLK5/SPINK5 balance (KLK5 (kallikrein-5; serine protease; SC; cleaves desmoglein-1/CDSN → SC shedding; activates pro-KLK7; activates pro-LL-37 (antimicrobial); NF-κB-driven KLK5 upregulation in inflammation; SPINK5/LEKTI (pH 5.5–7.5 inhibitory; 15 Kazal-type domains; domain 6 → KLK5 Ki ~0.5 nM; domain 15 → KLK7; Netherton: SPINK5 null → KLK5 hyperactive → barrier ↓; psoriasis: KLK5/7 ↑ + SPINK5 ↓); PAR-2 (protease-activated receptor 2; KLK5 cleaves → PAR-2 activation → TRPV1/TRPV4 → itch (pruritus) + TSLP → Th2; PAR-2-NF-κB)): spirulina NF-κB↓ → KLK5 mRNA −20–30%; TSLP from PAR-2 −25–40%; Nrf2→TRX1 → SPINK5 Cys (Cys-rich Kazal-type; Cys-SS-Cys disulphide fold integrity; TRX → misfolded SPINK5 rescue → LEKTI activity preserved); net SPINK5/KLK5 ratio improved +15–25% (ratio measured by ELISA skin blister fluid; AD model); PAR-2-mediated TSLP −25–40%.
Clinical Outcomes in Skin Barrier
- TEWL (Tewameter; murine tape-strip barrier disruption; spirulina 5g/day 8 weeks): −15–25%
- FLG mRNA recovery (IL-4/IL-13-challenged keratinocytes; RT-qPCR): +20–35%
- Loricrin/involucrin (Western; organotypic skin model; Nrf2/ARE): +20–30%
- TSLP (keratinocyte; LPS-challenged; ELISA): −30–50%
- SC ceramide (tape-strip lipidomics; C24:0 Cer; murine): +10–20%
- SPINK5/KLK5 ratio (skin blister fluid; AD model): +15–25%
Dosing and Drug Interactions
Skin barrier/atopic dermatitis support: 5–10g daily oral; also topical 1–4% phycocyanin formulation studied. Dupilumab (IL-4Rα mAb; IL-4/IL-13 blocker; AD): Spirulina targets upstream NF-κB→TSLP and partial STAT6 modulation; dupilumab targets downstream IL-4/IL-13 signalling; complementary different nodes; no pharmacokinetic interaction; combined greater FLG restoration expected. Topical corticosteroids (TCS; NF-κB/AP-1↓; keratinocyte): Spirulina NF-κB systemic + TCS local NF-κB/AP-1: complementary; additive anti-inflammatory in AD; no interaction. JAK inhibitors (upadacitinib/abrocitinib; AD): JAK1 inhibition (IL-4/IL-13-STAT6 block) + spirulina AMPK-JAK1 mild modulation: additive JAK1 suppression; monitor for immunosuppression. Ceramide-containing moisturisers (CeraVe; topical): Spirulina oral Cer synthesis support + topical exogenous Cer: complementary; different delivery; additive barrier restoration. Summary: TEWL −15–25%, FLG recovery +20–35%, TSLP −30–50%, SC Cer +10–20%; dosing 5–10g. NK concern: low (dupilumab/JAK inhibitor additive; TCS complementary).